Their findings suggest that in the treatment of breast cancer, PARP inhibitors are not cost-effective when compared to chemotherapy as they exceed WTP thresholds (WTP thresholds ranging up to USD 150,000 per QALY). Here, PARP1 is linked to breast carcinoma.